Want to see HK:3309 full AI Analyst Report?
3309 Stock Chart & Stats
HK$1.70
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$1.70
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.91 - HK$2.16
Previous CloseN/A
Volume360.00K
Average Volume (3M)495.46K
Market Cap
HK$1.15B
Enterprise ValueHK$1.30B
Total Cash (Recent Filing)HK$465.96M
Total Debt (Recent Filing)HK$426.78M
Price to Earnings (P/E)11.2
Beta1.07
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.15%
Share Statistics
EPS (TTM)0.08
Shares Outstanding1,232,342,900
10 Day Avg. Volume419,185
30 Day Avg. Volume495,465
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)1.17
Price to Sales (P/S)1.07
P/FCF Ratio9.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)HK$2.08B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent positive operating cash flow and persistent free cash flow through 2022–2025 provide durable internal funding for capex, clinic expansion and working capital. Reliable cash generation cushions earnings swings, supports debt servicing and enables strategic reinvestment over months-to-years.
Moderate, Manageable LeverageA moderate debt profile (D/E ~0.19–0.35) and steady asset base reduce insolvency risk and preserve financial flexibility. This leverage level supports growth investments without heavy interest strain, allowing the company to pursue capacity or network expansions while maintaining balance sheet resilience.
Revenue Expansion And Margin RecoveryMaterial revenue growth across multiple years and a rebound to positive net income in 2025 indicate underlying demand for ophthalmic services and intact unit economics. Healthy gross and EBITDA margins suggest the business can sustain profit once revenue trends stabilize and utilization improves.
Bears Say
Earnings VolatilityRepeated swings between profit and loss reduce predictability for investors and management, complicating multi-year budgeting and capacity planning. Structural volatility may reflect sensitivity to procedure volumes or pricing, increasing risk that short-term setbacks translate to longer profit interruptions.
Inconsistent Returns To ShareholdersIrregular shareholder returns signal uneven conversion of operations into investor value, weakening the company’s appeal to return-seeking stakeholders. This pattern suggests capital allocation or operational challenges that may persist absent more stable profit generation and clearer distribution policies.
Free Cash Flow Volatility And Data GapsWhile absolute cash generation is strong, volatile FCF growth and missing coverage metrics reduce confidence in forecasting sustainable cash available for dividends or debt paydown. Such variability raises financing uncertainty and complicates long-term planning for expansion or shareholder returns.
C-MER Eye Care Holdings Limited News
3309 FAQ
What was C-MER Eye Care Holdings Limited’s price range in the past 12 months?
C-MER Eye Care Holdings Limited lowest stock price was HK$0.91 and its highest was HK$2.16 in the past 12 months.
What is C-MER Eye Care Holdings Limited’s market cap?
C-MER Eye Care Holdings Limited’s market cap is HK$1.15B.
When is C-MER Eye Care Holdings Limited’s upcoming earnings report date?
C-MER Eye Care Holdings Limited’s upcoming earnings report date is Sep 01, 2026 which is in 29 days.
How were C-MER Eye Care Holdings Limited’s earnings last quarter?
C-MER Eye Care Holdings Limited released its earnings results on Mar 27, 2026. The company reported HK$0.042 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.042.
Is C-MER Eye Care Holdings Limited overvalued?
According to Wall Street analysts C-MER Eye Care Holdings Limited’s price is currently Overvalued.
Does C-MER Eye Care Holdings Limited pay dividends?
C-MER Eye Care Holdings Limited pays a Annually dividend of HK$0.03 which represents an annual dividend yield of 2.15%. See more information on C-MER Eye Care Holdings Limited dividends here
What is C-MER Eye Care Holdings Limited’s EPS estimate?
C-MER Eye Care Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does C-MER Eye Care Holdings Limited have?
C-MER Eye Care Holdings Limited has 1,232,342,900 shares outstanding.
What happened to C-MER Eye Care Holdings Limited’s price movement after its last earnings report?
C-MER Eye Care Holdings Limited reported an EPS of HK$0.042 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.568%.
Which hedge fund is a major shareholder of C-MER Eye Care Holdings Limited?
Currently, no hedge funds are holding shares in HK:3309
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
C-MER Eye Care Holdings Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.66%
12-Months-Change
Fundamentals
Return on Equity
2.15%
Trailing 12-Months
Asset Growth
0.46%
Trailing 12-Months
Company Description
C-MER Eye Care Holdings Limited
C-MER Medical Holdings Limited specializes in offering both medical treatments and therapeutic services for a variety of eye conditions. Its business activities are segmented into two primary areas: the delivery of ophthalmological services and the retail of vision-enhancing products. Established by Shun Chiu Lam on February 1, 2016, the organization's corporate headquarters are situated in Hong Kong.
Technical Analysis
Rici Healthcare Holdings Ltd.
―
EuroEyes International Eye Clinic Limited
―
Chaoju Eye Care Holdings Ltd.
―
Guangdong Kanghua Healthcare Co., Ltd. Class H
―
Town Health International Medical Group Ltd.
―